Biofrontera Inc. (BFRI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 6M 12M 18M Q3 '20: 3.3M Q4 '20: 8.6M Q1 '21: 4.7M Q2 '21: 5.9M Q3 '21: 4.3M Q4 '21: 9.2M Q1 '22: 9.8M Q2 '22: 4.5M Q3 '22: 4.3M Q4 '22: 10.1M Q1 '23: 8.7M Q2 '23: 5.8M Q3 '23: 8.9M Q4 '23: 10.6M Q1 '24: 7.9M Q2 '24: 7.8M Q3 '24: 9M Q4 '24: 12.6M Q1 '25: 8.6M Q2 '25: 9M Q3 '25: 7M Q4 '25: 17.1M Q1 '26: 10.1M Q2 '26: 12M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 1.5M 3M 4.5M Q3 '20: 2.8M Q3 '21: 4.3M Q3 '20 Q3 '21

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '20: -2.3M Q4 '20: -188K Q1 '21: -3.5M Q2 '21: -3.7M Q3 '21: -16.1M Q4 '21: -1.9M Q1 '22: -3.1M Q2 '22: -6.2M Q3 '22: -3.6M Q4 '22: -5.6M Q1 '23: -5.5M Q2 '23: -8.7M Q3 '23: -4.6M Q4 '23: -3.9M Q1 '24: -5.5M Q2 '24: -5.1M Q3 '24: -5M Q4 '24: -1.7M Q1 '25: -4.5M Q2 '25: -5.1M Q3 '25: -6.3M Q4 '25: 4.6M Q1 '26: -4.3M Q2 '26: -524K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '20: -3M Q4 '20: -186K Q1 '21: -3.5M Q2 '21: -3.7M Q3 '21: -16M Q4 '21: -14.5M Q1 '22: 5.6M Q2 '22: -850K Q3 '22: -2.6M Q4 '22: -2.8M Q1 '23: -7.5M Q2 '23: -9.8M Q3 '23: -6.3M Q4 '23: 3.5M Q1 '24: -10.4M Q2 '24: -257K Q3 '24: -5.7M Q4 '24: -1.4M Q1 '25: -4.2M Q2 '25: -5.3M Q3 '25: -6.6M Q4 '25: 5.6M Q1 '26: -4.8M Q2 '26: -604K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 200K 400K 600K Q3 '20: 446K Q3 '21: 41K Q3 '20 Q3 '21

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q4 '20: -663K Q1 '21: -3.4M Q2 '21: -1.1M Q3 '21: -1.2M Q4 '21: -21M Q1 '22: -2.1M Q2 '22: 125K Q3 '22: -5.9M Q4 '22: -8.3M Q1 '23: -3.7M Q2 '23: -10.3M Q3 '23: -2M Q4 '23: -8.9M Q1 '24: -3.3M Q2 '24: -4.7M Q3 '24: -1.2M Q4 '24: -1M Q1 '25: -4.1M Q2 '25: -3M Q3 '25: -3.8M Q4 '25: -2.4M Q1 '26: -70K Q2 '26: -1.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-12M -8M -4M 0 4M 8M 12M Q3 '21: -1.2M Q3 '22: -5.9M Q4 '22: -8.3M Q1 '23: -3.7M Q2 '23: -10.3M Q3 '23: -2M Q4 '23: -8.9M Q1 '24: -3.4M Q2 '24: -4.8M Q3 '24: -1.2M Q4 '24: -1M Q1 '25: -4.1M Q2 '25: -3M Q3 '25: -3.8M Q4 '25: -2.4M Q1 '26: -75K Q2 '26: -1.7M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q1 '21: 8M Q2 '21: 8M Q3 '21: 8M Q1 '22: 17.1M Q2 '22: 941.2K Q3 '22: 1.1M Q1 '23: 1.3M Q2 '23: 1.4M Q3 '23: 1.4M Q1 '24: 3.6M Q2 '24: 5.1M Q3 '24: 5.8M Q1 '25: 8.9M Q2 '25: 9.4M Q3 '25: 10.8M Q1 '26: 11.7M Q2 '26: 12.9M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q4 '21: -4.28 Q1 '22: -3.52 Q2 '22: -3.96 Q3 '22: -4.22 Q4 '22: -0.61 Q1 '23: -6.53 Q2 '23: -12.86 Q3 '23: -15.24 Q4 '23: -13.02 Q1 '24: -10.30 Q2 '24: -3.12 Q3 '24: 0.54 Q4 '24: -3.22 Q1 '25: -0.81 Q2 '25: -1.33 Q3 '25: -0.97 Q4 '25: -1.04 Q1 '26: -0.98 Q2 '26: -0.46 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.